1206 GMT - Novartis's earnings growth will stall in 2026 due to larger-than-expected losses from slowing sales of its Cosentyx autoimmune treatment, Intron Health analysts write. Cosentyx U.S. sales are likely to drop 17% mainly due to increased competition and lower prices and compared with consensus forecasts for a 10% rise, the analysts say. The decrease could cut Novartis's EBIT by about 5%, they add. Together with the Swiss pharma group's Entresto heart-failure drug loss of patent exclusivity, this will likely lead to flat earnings per share next year, the analysts write. Moreover, Novartis's long-term revenue growth remains weak and lags that of other major European drugmakers, the analysts add. Intron Health cuts its recommendation on Novartis's stock to hold from buy. Shares fall 0.4% Monday and are up 18% year to date. (william.gray@wsj.com)

(END) Dow Jones Newswires

October 13, 2025 08:11 ET (12:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.